Substantial improvement in β-cell function with initial combination therapy of sitagliptin and metformin in patients with type 2 diabetes after 1 year of treatment

被引：0
|
作者：
Williams-Herman, Debora
Xu, Lei
Davies, Michael J.
Stein, Peter P.
Amatruda, John M.
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A161 / A161
页数：1
相关论文
共 50 条
  • [1] Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes
    Williams-Herman, D.
    Xu, L.
    Teng, R.
    Golm, G. T.
    Johnson, J.
    Davies, M. J.
    Kaufman, K. D.
    Goldstein, B. J.
    [J]. DIABETES OBESITY & METABOLISM, 2012, 14 (01): : 67 - 76
  • [2] Two-year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycaemic control in patients with type 2 diabetes
    Qi, D. S.
    Teng, R.
    Jiang, M.
    Davies, M. J.
    Kaufman, K. D.
    Amatruda, J. M.
    Williams-Herman, D.
    [J]. DIABETOLOGIA, 2008, 51 : S36 - S36
  • [3] Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes
    Gallwitz, Baptist
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2011, 6 (04) : 543 - 556
  • [4] Initial combination therapy with sitagliptin, a selective DPP-4 inhibitor, and metformin leads to marked improvement in β-cell function in patients with type 2 diabetes
    Williams-Herman, Debora
    Xu, Lei
    [J]. DIABETES, 2007, 56 : A142 - A142
  • [5] Initial combination therapy with sitagliptin, a selective DPP-4 inhibitor, and metformin leads to marked improvement in β cell function in patients with type 2 diabetes
    Xu, L.
    Williams-Herman, D. E.
    [J]. DIABETOLOGIA, 2007, 50 : S365 - S365
  • [6] Initial Treatment with Sitagliptin as Monotherapy or Combination Therapy Improves Markers of β-Cell Function in Patients with Type 2 Diabetes
    Steinberg, Helmut
    Engel, Samuel S.
    Golm, Gregory T.
    Alba, Maria
    Langdon, Ronald B.
    Kaufman, Keith D.
    Goldstein, Barry J.
    [J]. DIABETES, 2011, 60 : A610 - A610
  • [7] FOUR YEAR OUTCOME OF INITIAL COMBINATION OF SITAGLIPTIN AND METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN REAL CLINICAL PRACTICE
    Ku, E. J.
    Jung, K. Y.
    Kim, Y. J.
    Kim, K. M.
    Moon, J. H.
    Choi, S. H.
    Park, K. S.
    Jang, H. C.
    Cho, Y. M.
    Lim, S.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S139 - S140
  • [8] Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study
    Ku, Eu Jeong
    Jung, Kyong Yeon
    Kim, Yoon Ji
    Kim, Kyoung Min
    Moon, Jae Hoon
    Choi, Sung Hee
    Cho, Young Min
    Park, Kyong Soo
    Jang, Hak Chul
    Lim, Soo
    Ahren, Bo
    [J]. PLOS ONE, 2015, 10 (06):
  • [9] Sitagliptin with metformin: Profile of a combination for the treatment of type 2 diabetes
    Gallwitz, Baptist
    [J]. DRUGS OF TODAY, 2007, 43 (10) : 681 - 689
  • [10] Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
    Williams-Herman, D.
    Johnson, J.
    Teng, R.
    Golm, G.
    Kaufman, K. D.
    Goldstein, B. J.
    Amatruda, J. M.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (05): : 442 - 451
12345